Can Praxbind Push Pradaxa Ahead?
Approval of antidote should give Boehringer Ingelheim’s anticoagulant a needed advantage in a tough market, but it has a short window before Portola’s Factor Xa antidote comes along.
Approval of antidote should give Boehringer Ingelheim’s anticoagulant a needed advantage in a tough market, but it has a short window before Portola’s Factor Xa antidote comes along.